Thermo Fisher Scientific Inc. TMO
699.65 USD +17.00 (+2.49%)
Nov 3, 2026, 3:25 PM EST
672.00 Day range 700.19
438.34 52-week range 709.18
- YTD
- +20.74%
- 1 year
- +23.86%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 752.12 +7.5% upside
Now 699.65
- Target (low)
- 590.00
- Target (mean)
- 752.12
- Target (high)
- 830.00
Ratings (0m) 27 23 buy · 3 hold · 1 sell
- Strong buy3
- Buy20
- Hold3
- Sell0
- Strong sell1
Recommendation trend
- This month 27
- 1 month ago 28
- 2 months ago 28
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 7.14 | 7.00 – 7.34 | 6.57 | +8.6% | 12.86B | +5.3% | 21 |
| Next quarter | 6.05 | 5.64 – 6.53 | 5.44 | +11.3% | 11.74B | +6.7% | 13 |
| Current year | 25.28 | 25.15 – 25.40 | 22.87 | +10.5% | 48.00B | +7.7% | 26 |
| Next year | 27.77 | 27.02 – 29.31 | 25.28 | +9.9% | 50.53B | +5.3% | 27 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Argus Research | Maintained | Buy | Buy |
| Oct 23, 2026 | Citigroup | Maintained | Buy | Buy |
| Oct 22, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 22, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 22, 2026 | Stifel | Maintained | Buy | Buy |
| Oct 22, 2026 | Baird | Maintained | Outperform | Outperform |
| Oct 13, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 3, 2026 | CLSA | Initiated | — | Outperform |
| Jul 27, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Jul 27, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 24, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Jul 24, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jun 11, 2026 | Piper Sandler | Initiated | — | Neutral |
| Jun 3, 2026 | HSBC | Downgrade | Buy | Hold |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 24, 2026 | Stifel | Maintained | Buy | Buy |
| Apr 24, 2026 | Baird | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jan 30, 2026 | Citigroup | Maintained | Buy | Buy |
| Jan 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jan 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 9, 2026 | Stifel | Maintained | Buy | Buy |
| Jan 7, 2026 | TD Cowen | Maintained | Buy | Buy |
| Dec 15, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Dec 11, 2025 | Citigroup | Upgrade | Neutral | Buy |
